IBRX News

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman

IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

Pomerantz LLP Issues Important Reminder to ImmunityBio, Inc. Investors – IBRX

IBRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP